Results 261 to 270 of about 399,504 (355)

Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors.

ACS Medicinal Chemistry Letters, 2015
A. C. Hart, Gretchen M. Schroeder, H. Wan, J. Grebinski, J. Inghrim, J. Kempson, Junqing Guo, W. Pitts, J. Tokarski, J. Sack, Javed A Khan, J. Lippy, M. V. Lorenzi, D. You, T. Mcdevitt, R. Vuppugalla, Yueping Zhang, L. Lombardo, G. Trainor, A. Purandare   +19 more
semanticscholar   +1 more source

IL-6; janus kinase-2 (JAK-2); JAK-3 [PDF]

Science-Business eXchange, 2011
openaire   +1 more source

Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera. [PDF]

Malays J Med Sci, 2020
Yikilmaz AŞ, Akinci S, Bakanay ŞM, Dilek İ.   +3 more
europepmc   +1 more source

Long non-coding RNA musculin antisense RNA 1 promotes proliferation and suppresses apoptosis in osteoarthritic chondrocytes via the microRNA-369-3p/Janus kinase-2/ signal transducers and activators of transcription 3 axis. [PDF]

Bioengineered, 2022
Tang Z, Gong Z, Sun X.
europepmc   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

Allergy, EarlyView.
ABSTRACT Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment ...
Marjolein S. de Bruin‐Weller, Celeste M. Boesjes, Roselie A. Achten, Lisa A. Beck, Alan D. Irvine, Christian Vestergaard, Marlies de Graaf, Femke van Wijk, Daphne S. Bakker, Stephan Weidinger   +9 more
wiley   +1 more source

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. [PDF]

Hemasphere, 2021
Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN.   +14 more
europepmc   +1 more source

Club Cells in Nasal Epithelial Repair: Insights From an IL‐13‐Induced Inflammatory Model

Allergy, EarlyView.
Four inflammatory endotypes of CRSwNP, defined by eosinophil and neutrophil infiltration, show distinct patterns of basal, club, ciliated, and goblet cell expression in nasal epithelium. Using an ALI‐HNECs model, we demonstrate that IL‐13 impairs mucociliary function by promoting club‐to‐goblet cell differentiation while inhibiting club‐to‐ciliated ...
Zhi‐Qun Huang, Jing Liu, Jing Ye, Li‐Ying Sun, Hsiao Hui Ong, Yang Peng, Bing‐Qi Lin, Jun‐Hao Tu, Ke‐Shuang Wang, Yi‐Shan Xiong, Qing Luo, Mark Thong, Yu Xu, De‐Yun Wang   +13 more
wiley   +1 more source

Homeodomain-containing gene 10 contributed to breast cancer malignant behaviors by activating Interleukin-6/Janus kinase 2/Signal transducer and activator of transcription 3 pathway.

Bioengineered, 2022
Shen J, Wang M, Li F, Yan H, Zhou J.
europepmc   +1 more source

Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in Apc^Min/+ mice. [PDF]

Int J Immunopathol Pharmacol, 2021
Yang K, Zhu J, Luo HH, Yu SW, Wang L.
europepmc   +1 more source